Day

June 28, 2017
A phase 1b study of isatuximab plus lenalidomide and dexamethasone for relapsed/refractory multiple myeloma’ is a study intended to assess the safety, efficacy and pharmacokinetics of the anti-CD38 monoclonal antibody isatuximab given in 2 different regimens in combination with lenalidomide and dexamethasone. The study included 57 patients in total with a confirmed diagnosis of multiple myeloma...
Continue Reading

Floor 7, 90 The Terrace
Wellington Central
New Zealand